Treatment of experimental leishmaniasis with the immunomodulators, imiquimod and S-28463 : efficacy and mode of action
There are currently no ideal treatments or acceptable vaccines for cutaneous leishmaniasis, a worldwide health problem caused by infection with a number of species of the dimorphic protozoa Leishmania. Therefore, there is an urgent need to search for simple, safe, effective, and affordable treatment...
Main Author: | Buates, Sureemas. |
---|---|
Other Authors: | Matlashewski, Greg (advisor) |
Format: | Others |
Language: | en |
Published: |
McGill University
2001
|
Subjects: | |
Online Access: | http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=36878 |
Similar Items
-
Immunochemotherapy in experimental leishmaniasis
by: Eslami, Zohreh.
Published: (1996) -
Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance
by: Loiseau P.M., et al.
Published: (2011-05-01) -
Alternative to Chemotherapy—The Unmet Demand against Leishmaniasis
by: Nicky Didwania, et al.
Published: (2017-12-01) -
Exploitation of parasite derived antigen in therapeutic success of human cutaneous leishmaniasis in Brazil
by: Loic Monjour, et al.
Published: (1994-09-01) -
Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal leishmaniasis refractory to antimony: a case report
by: Roberto Badaro, et al.